World's leading maker of cochlear implants, restoring hearing for people with severe hearing loss.
World's leading maker of cochlear implants, restoring hearing for people with severe hearing loss.
Sells an implant fitted once by surgery, then earns again as recipients upgrade the external sound processor every few years, a recurring line that rests on its installed base. Government and insurance reimbursement pays for most devices, so public tenders and coverage decisions matter. Most sales are outside Australia.
In one line: A mini-Medtronic focused solely on cochlear implants.
Moat: wide (IP / patents, regulatory licence, switching costs). Global installed-base leadership, deep surgeon relationships and patent-protected implant technology.
Headquarters: Sydney, Australia · Founded: 1981 · Employees: 5,400
Size Cochlear (COH.AX) is an Australia Health Care company (Medical Specialties) with a market value of $6.72B, the 50th largest of 317 Australia companies the cockpit tracks. Shares closed at A$153.17 on 18 Nov 2026.
Performance Over six months the shares gained 57.8%, against +25.7% for the median peer and +1.2% for the Australia market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue fell 0.9% over the last twelve months (peer median +8.1%); the operating margin is 12.9% (peer median 17.3%).
Valuation It trades at 29.1× forward earnings against a peer median of 20.8× (5th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.4 points above its cost of capital (9.5% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$2.33B | A$2.33B | A$2.36B | A$2.26B | A$1.96B |
| Revenue growth | — | -1% | +4% | +15% | — |
| Gross profit | A$1.65B | A$1.65B | A$1.74B | A$1.70B | A$1.47B |
| EBITDA | A$407M | A$407M | A$600M | A$606M | A$493M |
| Net income | A$147M | A$147M | A$389M | A$357M | A$301M |
| Free cash flow | A$307M | A$307M | A$175M | A$326M | A$312M |
| Capital expenditure | A$90.7M | A$90.7M | A$103M | A$89.8M | A$95.9M |
| Total debt | n/a | A$213M | A$236M | A$244M | A$202M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Cochlear COH.AX | $6.72B | +58% | -1% | 13% | 29.1× | 23.9% |
| Sonova SOON.SW | $19.8B | +40% | -6% | 23% | 25.3× | 6.0% |
| Demant A/S DEMANT.CO | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COH.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.9% | +12.8% | 10th lowest of 21 |
| 6-month return | +57.8% | +25.7% | 3rd highest of 21 |
| Distance from 52-week high | -46.2% | -6.1% | 2nd lowest of 21 |
| Revenue growth (TTM) | -0.9% | +8.1% | 5th lowest of 21 |
| Operating margin | 12.9% | 17.3% | 4th lowest of 21 |
| Forward P/E | 29.1× | 20.8× | 5th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 23.9% | 9.8% | 2nd most demanding of 19 |
| Growth delivered (Del g) | +9.3% | +9.7% | 9th lowest of 19 |
| Hurdle (Req g minus delivered) | +14.6 pp | +1.4 pp | 2nd most demanding of 19 |
| ROIC minus cost of capital | +2.4 pp | +3.5 pp | 7th lowest of 21 |
| EV / EBITDA | 24.7× | 14.0× | most expensive of 18 |
| Net debt / EBITDA | 0.1× | 0.9× | 8th least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cochlear COH.AX | Australia | $6.72B | +58% | -1% | 13% | 29.1× | 23.9% | +9.3% |
| Lantheus LNTH | United States | $6.67B | +6% | +2% | 19% | 15.5× | 0.4% | +35.3% |
| ConvaTec CTEC.L | United Kingdom | $6.78B | +37% | +2% | 16% | 17.7× | 17.2% | +4.6% |
| Ypsomed YPSN.SW | Switzerland | $6.83B | +27% | -13% | 30% | 31.7× | n/a | n/a |
| Teleflex TFX | United States | $6.58B | +23% | -29% | 12% | 16.7× | 16.5% | -4.7% |
| Asahi Intecc 7747.T | Japan | $7.09B | +24% | +23% | 32% | 29.7× | 15.1% | +18.8% |
| Bausch + Lomb BLCO.TO | Canada | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% | +10.0% |
| Getinge GETI-B.ST | Sweden | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% | +3.2% |
| APT Medical 688617.SS | China | $6.06B | +23% | +28% | 37% | 38.6× | 9.0% | +40.1% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.50B | +21% | +7% | 43% | 26.9× | 2.9% | +15.7% |
| Sysmex 6869.T | Japan | $8.06B | +58% | +8% | 13% | 32.0× | 4.4% | +10.4% |
| Haemonetics HAE | United States | $5.59B | +106% | +4% | 19% | 20.7× | 10.9% | +8.9% |
| Shimadzu 7701.T | Japan | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% | +7.3% |
| LivaNova LIVN | United States | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% | +8.2% |
| Merit Medical Systems MMSI | United States | $5.15B | +33% | +9% | 14% | 19.1× | 12.6% | +9.5% |
| Globus Medical GMED | United States | $9.34B | -16% | +13% | 23% | 13.7× | 4.6% | +30.1% |
| Intco Medical Technology 300677.SZ | China | $4.82B | -2% | +33% | 20% | 18.5× | -3.5% | -6.4% |
| DiaSorin DIA.MI | Italy | $4.81B | +24% | -3% | 24% | 20.5× | 4.1% | +6.3% |
| MiniMed MMED | United States | $4.78B | +46% | +14% | 14% | 26.3× | n/a | n/a |
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |